32.87
0.13 (0.40%)
| Previous Close | 32.74 |
| Open | 32.61 |
| Volume | 99,594 |
| Avg. Volume (3M) | 581,962 |
| Market Cap | 1,627,225,984 |
| Price / Sales | 3.21 |
| Price / Book | 3.57 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -7.95% |
| Operating Margin (TTM) | -4.82% |
| Diluted EPS (TTM) | -0.810 |
| Quarterly Revenue Growth (YOY) | 13.60% |
| Total Debt/Equity (MRQ) | 17.03% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | 22.19 M |
| Levered Free Cash Flow (TTM) | -10.42 M |
| Return on Assets (TTM) | -3.70% |
| Return on Equity (TTM) | -8.38% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bearish | Mixed |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | AtriCure, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 3.37% |
| % Held by Institutions | 103.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (JMP Securities, 82.54%) | Buy |
| 60.00 (Citizens Capital Markets, 82.54%) | Buy | |
| Median | 59.00 (79.50%) | |
| Low | 44.00 (Needham, 33.86%) | Buy |
| Average | 55.50 (68.85%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 30.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 30 Apr 2025 | 60.00 (82.54%) | Buy | 29.91 |
| Needham | 30 Apr 2025 | 44.00 (33.86%) | Buy | 29.91 |
| UBS | 30 Apr 2025 | 58.00 (76.45%) | Buy | 29.91 |
| Citizens Capital Markets | 02 Apr 2025 | 60.00 (82.54%) | Buy | 34.13 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 May 2025 | Announcement | AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 29 Apr 2025 | Announcement | AtriCure Reports First Quarter 2025 Financial Results |
| 10 Apr 2025 | Announcement | AtriCure Announces First Use of the AtriClip PRO-Mini® Device |
| 08 Apr 2025 | Announcement | AtriCure to Announce First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |